Johnson & Johnson MedTech’s (NYSE: JNJ) + Ethicon today announced the European approval and introduction of Ethizia, its hemostatic sealing patch.

The adjunctive hemostat solution helps to achieve sustained hemostasis in difficult to control bleeding situations. Ethizia features unique synthetic polymer technology for maximum adaptability. Ethicon said it’s the first and only hemostatic matrix designed to be equally active and efficacious on both sides.

Ethizia offers easy handling in both open and minimally invasive surgery. It’s capable of being stuffed, rolled, pulled apart, trimmed and tailored, Ethicon said in a news release. In 80% of clinical trial patients studied, the patch stopped bleeding in 30 seconds. That averages out to six times faster than the leading fibrin sealant patch, Ethicon said.

The patch received CE mark approval as an adjunctive hemostate for disruptive bleeding on internal organs, except cardiovascular and neurological. Ethicon expects to launch in EMEA in the first quarter of 2024. It anticipates other key markets, including North America, to follow once it garners regulatory approvals.

Vladimir Makatsaria, company group chair, Ethicon, said the patch reflect’s Ethicon’s commitment to safeguarding patients from surgical complications.

“Disruptive bleeding can contribute to serious complications, and with the addition of Ethizia to our portfolio, we are well positioned to deliver critical hemostasis solutions for patients,” Makatsaria said.

Ethicon acquired GATT Technologies, a maker of hemostatic and sealant products, in May 2022. That acquisition, with the addition of the GATT synthetic polymer technologies, enabled the development of Ethizia.